Olubukola Ayodele, Breast Cancer Lead at University Hospitals of Leicester NHS Trust, shared a post on LinkedIn:
“Oligometastatic breast cancer is one of the most complex and misunderstood areas in oncology.
For many patients, hearing the word “metastatic” immediately feels synonymous with incurable disease.
But biology is not always binary.
There is increasing recognition that some patients sit in a middle ground between localised and widespread metastatic disease. This is what we call “oligometastatic breast cancer”.
Broadly, this refers to:
- 1–5 metastatic lesions
- Usually involving 1–2 organs
- Where all visible disease can potentially be treated with curative-intent local therapy such as surgery or stereotactic body radiotherapy (SBRT)
Examples may include:
- a solitary liver metastasis
- 2 small lung nodules
- isolated bone metastases
Diffuse multiorgan disease would generally not fit this definition.
But this is where the challenge lies.
Oligometastatic disease is probably not a single disease state. It is more likely a spectrum of biology.
Some tumours behave indolently for years. Others may only appear oligometastatic on imaging while microscopic disease already exists elsewhere.
This uncertainty is why both clinicians and patients struggle with decision-making.
Should we treat aggressively with curative intent?
Can local therapy genuinely alter the natural history of metastatic disease?
The recent OLIGOMA trial, presented at ESTRO 2026, adds important data to this discussion.
The study enrolled 87 patients with 1–5 metastatic lesions. Patients received standard systemic therapy alone or systemic therapy plus SBRT to all metastatic sites.
Median progression-free survival was:
- 35.8 months with SBRT + systemic therapy
vs - 20.4 months with systemic therapy alone
This corresponded to:
- HR 0.48
- p=0.021
Importantly, quality of life did not significantly worsen despite additional radiotherapy.
The study was small and we still need mature overall survival data. But it reinforces an important shift in oncology:
Metastatic breast cancer is not always one uniform entity.
As systemic therapies improve and patients live longer, we are increasingly identifying a subgroup where local eradication of metastases may matter.
Tumour biology matters.
Disease-free interval matters.
Response to systemic therapy matters.
Patient goals matter.
The future is no longer: “early” versus “metastatic”.
It would instead be identifying who benefits from systemic control alone and who may benefit from systemic therapy plus local eradication of disease.”
Other articles featuring Olubukola Ayodele on OncoDaily.